Uyen Y. Doan, Viet Nam

Pasteur Institution HCMC Clinical Research Centre

Author Of 2 Presentations

INCREASED PCV10 IMMUNOGENICITY FOLLOWING A TWO-DOSE PRIMARY SERIES SEPARATED BY 4 MONTHS COMPARED WITH 2 MONTHS IN VIETNAMESE INFANTS (ID 963)

IMMUNOGENICITY OF A SINGLE DOSE OF PCV10 OR PCV13 AT 2 MONTHS OF AGE IN VIETNAM (ID 1007)

Abstract

Background

A 1+1 pneumococcal conjugate vaccine (PCV) schedule would increase its affordability for low and middle-income countries. The Vietnam Pneumococcal Trial II includes infants randomised to receive a 1+1 schedule of PCV10 or PCV13 at 2 and 12 months of age. This study measured the immunogenicity of a single dose of either PCV given at 2 months of age.

Methods

Serotype-specific IgG was measured at 3 and 12 months of age in PCV-vaccinated and unvaccinated controls using a WHO ELISA method.

Results

At 3 months, both vaccinated groups had higher antibody levels than controls for 7/10 serotypes (all except 6B, 14, 23F). The PCV10 group had higher antibody levels than the PCV13 group for 5/10 serotypes. Similar results were seen at 12 months, with higher antibody levels for all serotypes in the PCV10 group and 8/10 serotypes (all except 6V, 23F) in the PCV13 group compared with controls and higher antibody levels in the PCV10 than the PCV13 group for 7/10 serotypes.

Conclusions

A single dose of PCV in infancy is immunogenic and likely to provide some direct protection until the time of the booster dose. There may be a difference in the degree of protection offered by different PCVs.

Hide